| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.5 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |